BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mederi Therapeutics Inc. Release: New Data Identifies Stretta(R) Mechanism in the Treatment of Gastroesophageal Reflux Disease (GERD)


12/5/2011 11:00:58 AM

·

·

GREENWICH, Conn., Dec. 5, 2011 /PRNewswire/ -- Mederi Therapeutics Inc. today announced the results of a novel, double-blind, sham-controlled study of Stretta for treatment of gastroesophageal reflux disease (GERD). The study evaluated the specific mechanism of action in the application of radiofrequency (RF) energy. This ground-breaking research suggests the mechanism by which Stretta Therapy causes a decrease in transient lower esophageal sphincter (LES) relaxations and an increase in gastric yield pressure, and therefore reduces reflux; and, as a result, improves symptoms in patients with medically refractory GERD. The study results were published in the American Journal of Gastroenterology.

"In this double-blind, sham-controlled study, our data confirms that Stretta improves the physiology of the lower esophageal sphincter, and that this is the likely mechanism for symptom improvement in GERD," said Jan Tack, M.D., Ph.D., one of the study's authors and Head of Clinic in the Department of Gastroenterology in the Center for Gastroenterological Research at the University of Leuven in Leuven, Belgium. "In addition to the noted effectiveness of the Stretta treatment, we believe that the method we employed in the study was able to exclude fibrosis as the underlying cause of the observed significant decrease in GEJ compliance."

"Professor Tack and his colleagues have helped us all take a major step forward to further explain and clarify this mechanism for Stretta, said Dr. Mark D. Noar, Director at the Heartburn and Reflux Study Center, Towson, MD. "These findings on the mechanism of action explain the results both medical professionals and their patients, with medically refractory GERD, have come to expect from Stretta."

"These results add to the significant body of research on Stretta. The treatment works exceptionally well to reduce or eliminate symptoms in sufferers of GERD, but exactly how it works is now more clearly understood," said Will Rutan, CEO of Mederi Therapeutics, manufacturer of Stretta. "With 67 publications supporting Stretta as a safe, effective, and durable treatment, Stretta offers an excellent alternative to invasive surgery."

Additional information is available in Am J Gastroenterol advance online publication, 22 November 2011; doi:10.1038/ajg.2011.395, http://www.nature.com/ajg/journal/vaop/ncurrent/abs/ajg2011395a.html, and at www.mederitherapeutics.com.

ABOUT STRETTA
Stretta Therapy is an effective treatment that is a minimally invasive option for patients who do not respond well to medical management. Stretta involves delivery of radiofrequency energy to the LES and gastric cardia, which has been shown in numerous clinical studies to be a safe, effective, and durable therapeutic option. Stretta does not preclude next steps with more invasive procedures when indicated.

ABOUT MEDERI®
Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

Contact: Sheila Doyle, 203-930-9980, sdoyle@mederitherapeutics.com

SOURCE Mederi Therapeutics Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES